SCHEMBL17826329

SCHEMBL17826329

CC(=O)OC1C=CC(O)C(C)C1CC=C(C)C

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
CA12 O43570 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA1 P00915 1/20 0.31
CYP3A4 P08684 2/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18022186 0.77
SCHEMBL18023678 0.77
SCHEMBL17826336 0.75 MAPT (0.33) MAPTCYP3A4CYP2C19
SCHEMBL13606432 0.69 CA12 (0.43) MAPTCA12CA2CA9CA1
SCHEMBL18022185 0.67
SCHEMBL19035782 0.66 CA12 (0.34) MAPTCA12CA2CA9CA1
SCHEMBL18022149 0.65 ABCB11 (0.32)
SCHEMBL18034098 0.64 KMT2A (0.50) MAPTCYP3A4CYP2C19
SCHEMBL18022158 0.62 ALDH1A1 (0.37) MAPTCYP3A4CYP2C19
SCHEMBL17409119 0.61 CA12 (0.38) MAPTCA12CA2CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2958883-B1 CYCLOHEXENONE COMPOSITIONS AND PROCESS FOR MAKING THEREOF GOLDEN BIOTECHNOLOGY CORP (US) 2019-01-30 EP disclosed
US-20160251308-A1 Cyclohexenone Compositions and Process for Making Thereof GOLDEN BIOTECHNOLOGY CORP (US) 2016-09-01 US disclosed
US-20160251308-A1 Cyclohexenone Compositions and Process for Making Thereof GOLDEN BIOTECHNOLOGY CORP (US) 2016-09-01 US disclosed
WO-2016133940-A1 ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF GOLDEN BIOTECHNOLOGY CORPORATION (US) 2016-08-25 WO disclosed
US-20160237012-A1 ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF GOLDEN BIOTECHNOLOGY CORPORATION 2016-08-18 US disclosed
US-20160237012-A1 ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF GOLDEN BIOTECHNOLOGY CORPORATION 2016-08-18 US disclosed
US-9365481-B2 Cyclohexenone compositions and process for making thereof GOLDEN BIOTECHNOLOGY CORPORATION (US) 2016-06-14 US disclosed
US-9365481-B2 Cyclohexenone compositions and process for making thereof GOLDEN BIOTECHNOLOGY CORPORATION (US) 2016-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237012-A1 ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF MCL1, HCCS, CASP3 MAPT 3911/4885CA12 3511/4885CA2 4138/4885
US-20160251308-A1 Cyclohexenone Compositions and Process for Making Thereof HSD17B7, CYP17A1, CYP51A1 MAPT 4072/4885CA12 1758/4885CA2 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.